RUXOLITINIB

Brand name:

• Jakavi®

Pharmaceutical company:

Novartis Pharmaceuticals Australia Pty Limited

Condition/indication:
(therapeutic use)

• Graft versus host disease

PBAC Submission type:

Change to PBS listing (Category 1)

Comment:

--

Public Summary Document:

PBAC Public Summary Documents – July 2022

Related medicines:

--

Submission received for:

July 2022 PBAC meeting

Opportunity for consumer comment:

Open 30/03/2022 and close 25/05/2022 (see PBS Website)

PBAC meeting:

Held on 06/07/2022

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

28/11/2022

Lodgement of required documentation:

14/12/2022

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 10/01/2023

Status:

Finalised

Government processes:

Commenced on 10/01/2023

Medicine listed on the PBS:

01/04/2023 (see PBS schedule)

---